Our results support the notion that PARP inhibitors administered in combination with immunotherapy using EGFR/Notch bsAbs have broad potential for the treatment of various tumours beyond hereditary BRCA1-deficient and BRCA2-deficient tumours, including lung cancer. This evidence concerns the gene BRCA1 and neoplasm.